ArticleFEBS open bio2021
Astragaloside IV protects against iron loading-induced abnormal differentiation of bone marrow mesenchymal stem cells (BMSCs).
Article in FEBS open bio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Targeting ferroptosis in osteoporosis: mechanisms and natural products therapies.Frontiers in pharmacology · 2026Review
- Effects of astragaloside IV on the proliferation and osteogenic differentiation of human jaw bone marrow mesenchymal stem cells in vitro.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- [Effect of astragaloside IV on osteogenic differentiation of BMSCs in osteoporotic rats via regulation of miR-21 and inhibition of the Notch signaling pathway].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025Article
- Astragaloside IV attenuates glucocorticoid-induced osteoclastogenesis and bone loss via the MAPK/NF-κB pathway.BMC complementary medicine and therapies · 2025Article
- Plant-derived food bioactives in bone health: from multi-targeted roles to molecular mechanisms in osteoporosis.Frontiers in nutrition · 2025Review
- A potential function for MicroRNA-124 in normal and pathological bone conditions.Non-coding RNA research · 2024Review
- Astragali Radix: comprehensive review of its botany, phytochemistry, pharmacology and clinical application.Archives of pharmacal research · 2024Review
- Natural compounds and mesenchymal stem cells: implications for inflammatory-impaired tissue regeneration.Stem cell research & therapy · 2024Review
- Notoginsenoside R1 promotes osteogenic differentiation of human bone marrow mesenchymal stem cells via ERα/GSK-3β/β-catenin signalling pathway.International journal of experimental pathology · 2024Article
- The Therapeutic Effect of Natural Compounds on Osteoporosis through Ferroptosis.Current medicinal chemistry · 2024Review
- Pharmacological Effects of Astragaloside IV: A Review.Molecules (Basel, Switzerland) · 2023Review
- Anti-inflammatory and antioxidant traditional Chinese Medicine in treatment and prevention of osteoporosis.Frontiers in pharmacology · 2023Review
- The delivery of miR-21a-5p by extracellular vesicles induces microglial polarization via the STAT3 pathway following hypoxia-ischemia in neonatal mice.Neural regeneration research · 2022Article
- Therapeutic Effect of Astragali Radix Extract Injection Combined with Bone Marrow Mesenchymal Stem Cells in Bleomycin-Induced Pulmonary Fibrotic Rats.Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iron loading has been reported to be a common stress in the development of cells, and this might be related to bone loss and osteoporosis. Astragaloside IV (ASI-IV), a pure compound derived from Radix Astragali, has been reported to exhibit cardioprotective, anti-inflammatory, antioxidant, antiasthmatic and anticancer effects. The aim of this study was to investigate whether ASI-IV could reverse iron loading-induced inhibition of cell viability, proliferation, pluripotency and osteogenesis and promote adipogenesis of bone marrow mesenchymal stem cells (BMSCs). Ferric ammonium citrate (FAC) was used to stimulate iron loading conditions. ASI-IV was observed to ameliorate the FAC-induced reduction of cell viability, proliferation, pluripotency and osteogenesis of BMSCs. In addition, ASI-IV could block the increased adipogenesis of BMSCs after FAC treatment. We intraperitoneally injected mice with 250 mg·kg
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.